Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease

Alimentary Pharmacology & Therapeutics, Год журнала: 2024, Номер 60(8), С. 1033 - 1041

Опубликована: Авг. 8, 2024

The diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) requires at least one five cardiometabolic criteria. It is unclear whether these criteria can be used as predictors and treatment targets for complications including liver-related events major adverse cardiovascular (MACE).

Язык: Английский

---

Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge

Metabolism and Target Organ Damage, Год журнала: 2024, Номер 4(3)

Опубликована: Июнь 26, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) stands as an independent risk factor for cardiovascular (CVD), which is the leading cause of mortality among MASLD patients. The diverse spectrum cardio-nephro-metabolic and vascular manifestations inherent in highlights complex profile CVD associated with this condition. However, current approaches to assessing lack specificity, predominantly relying on traditional markers. Although it widely accepted that patients advanced fibrosis are more prone risk, recent evidence suggests isolated focus may overlook remarkable phenotypic variability across entire population. Emerging data indicate a progressive escalation parallel severity MASLD, highlighting need precise staging inform accurate assessment. To address challenge, we propose novel sequential approach assessment MASLD. While factors remain essential, incorporating liver-specific parameters enhances stratification guides targeted interventions mitigate substantial burden vulnerable This involves initial screening using FIB-4 NAFLD score, followed by imaging-based non-invasive techniques individuals at intermediate-high fat quantification low-risk individuals. Future prospective investigations should simultaneous use biomarkers imaging modalities evaluate, sex-specific manner, efficacy proposed determine optimal thresholds steatosis

Язык: Английский

---

Is liver fibrosis more advanced in MetALD than in MASLD?

Journal of Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Июль 1, 2024

Язык: Английский

---

Steatotic Liver Disease: Navigating Pathologic Features, Diagnostic Challenges, and Emerging Insights

Advances in Anatomic Pathology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 17, 2025

Steatotic liver disease (SLD) is now used as an overarching category encompassing five subcategories: metabolic dysfunction-associated steatotic (MASLD), and alcohol related/associated (MetALD), alcohol-related/associated (ALD), SLD with specific etiology, cryptogenic SLD. This review summarizes foundational recent advances in the histologic evaluation of SLD, including common pathologic features across all subcategories, distinctions associated different etiologies, scoring grading systems, evolution digital pathology techniques for assessment.

Язык: Английский

---

Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease

Annals of Hepatology, Год журнала: 2025, Номер unknown, С. 101907 - 101907

Опубликована: Март 1, 2025

Язык: Английский

---

Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Characterising the phenotypic features of individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) can help identify high-risk subpopulations within this group. High-sensitivity troponin (hs-troponin) is a significant risk factor for future cardiovascular events. We studied association hs-troponin in absence all-cause and cause-specific mortality among MASLD. used National Health Nutrition Examination Survey 1999-2004 linked dataset through 2019. Cox regression models to assess between MASLD without disease. During median follow-up period 17.5 years (IQR: 15.9-19.1), higher levels T were associated progressively hazards mortality, which remained after adjustment demographic, clinical, lifestyle factors. There was 29% (hazard ratio [HR]: 1.29, 95% confidence interval [CI]: 1.16-1.44) increase 44% (HR: 1.44, CI: 1.20-1.72) every rise 1-standard deviation T. A (p trend) noted 3 I assays, similar no cancer-related mortality. Screening or at-risk group that have predominantly due disease-related population

Язык: Английский

---

AI‐Based Platelet‐Independent Noninvasive Test for Liver Fibrosis in MASLD Patients

JGH Open, Год журнала: 2025, Номер 9(4)

Опубликована: Апрель 1, 2025

ABSTRACT Background and Aim Noninvasive tests (NITs), such as platelet‐based indices ultrasound/MRI elastography, are widely used to assess liver fibrosis in metabolic dysfunction‐associated steatotic disease (MASLD). However, platelet counts not routinely included Japanese health check‐ups, limiting their utility large‐scale screenings. Additionally, while effective, is costly less accessible routine practice. Most existing AI‐based models incorporate these markers, restricting applicability. This study aimed develop a simple yet accurate AI model for staging using only demographic biochemical markers. Methods retrospective analyzed biopsy‐proven data from 463 MASLD patients. Patients were randomly assigned training ( N = 370, 80%) test 93, 20%) cohorts. The incorporated age, sex, BMI, diabetes, hypertension, hyperlipidemia, blood markers (AST, ALT, γ‐GTP, HbA1c, glucose, triglycerides, cholesterol). Results Support Vector Machine demonstrated high diagnostic performance, with an area under the curve (AUC) of 0.886 detecting significant (≥ F2). AUCs advanced F3) cirrhosis (F4) 0.882 0.916, respectively. Compared FIB‐4, APRI, FAST score (0.80–0.96), SVM achieved comparable accuracy eliminating need count or elastography. Conclusion accurately assesses patients without requiring Its simplicity, cost‐effectiveness, strong performance make it well‐suited screenings clinical use.

Язык: Английский

---

Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction‐Associated Steatotic Liver Disease

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Апрель 10, 2025

ABSTRACT Background and Aims MicroRNAs (miRNAs) are short non‐coding oligonucleotides involved in the post‐transcriptional regulation of gene expression. We investigated association between miRNome profile circulating extracellular vesicles (EVs) metabolic derangements, hepatic pro‐inflammatory cytokines, liver damage across histological spectrum dysfunction‐associated steatotic disease (MASLD). Methods EV miRNAs expression was determined by NGS (NextSeq550, Illumina Inc) 228 biopsy‐proven MASLD patients. In vivo studies were performed a subgroup 54 patients tracer infusion ([6,6‐ 2 H ]glucose [ 5 ]glycerol) to assess glucose lipid fluxes insulin resistance (IR) adipose tissue. Results Seven (miR‐27b‐3p, miR‐30a‐5p, miR‐122‐5p, miR‐375‐3p, miR‐103a‐3p, let‐7d‐5p, let‐7f‐5p) differentially expressed according diagnosis steatohepatitis presence significant fibrosis ( F ≥ 2), thus marking subjects with ‘at‐risk MASH’. studies, above‐reported had strongest associations metabolism: miR‐122‐5p miR‐375‐3p levels directly correlated free fatty acids (FFAs) tissue (AT)‐IR, while let‐7d‐5p let‐7f‐5p inversely lipolysis, FFAs, progressively decreased AT‐IR severity. addition, which increased increasing degrees AT‐IR. Conclusions Our results suggest an intertwined connection let‐7 family modulating derangements inflammatory pathways MASH’, paving basis for further aiming at investigating their potential therapeutic value.

Язык: Английский

---

Deep Learning-Based Prediction Models for Liver-Related and Cardiovascular Events in Steatotic Liver Disease

Опубликована: Янв. 1, 2025

Язык: Английский

---

MetALD: clinical aspects, pathophysiology and treatment

JHEP Reports, Год журнала: 2024, Номер 7(2), С. 101250 - 101250

Опубликована: Ноя. 2, 2024

Язык: Английский

---